MedTrace Logo

A Single Dose Escalation Study of HHT201 in Healthy Subjects

NCT06373094 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-04-18

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201 in healthy subjects.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Donepezil Dihydroxynaphthalate for Injection

HHT201 will be injected into the muscle of gluteus.

Sponsors & Collaborators

  • Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Dongqing Lv · Zhejiang Taizhou Hospital Luqiao Hospital (Enze Hospital)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06373094 on ClinicalTrials.gov